IGC Pharma
About: IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Employees: 70
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.07% less ownership
Funds ownership: 3.67% [Q4 2024] → 3.6% (-0.07%) [Q1 2025]
14% less capital invested
Capital invested by funds: $954K [Q4 2024] → $817K (-$138K) [Q1 2025]
17% less funds holding
Funds holding: 30 [Q4 2024] → 25 (-5) [Q1 2025]
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Research analyst outlook
We haven’t received any recent analyst ratings for IGC.
Financial journalist opinion
Based on 5 articles about IGC published over the past 30 days
Neutral
Accesswire
1 day ago
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection
- Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer's diagnostics - POTOMAC, MD / ACCESS Newswire / July 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced the development of MINT-AD, Multimodal Interpretable Transformer for Alzheimer's, the Company's proprietary AI-powered diagnostic platform designed to identify individuals at high risk of cognitive decline years before symptoms appear. MINT-AD leverages diverse data sources including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.
Neutral
Accesswire
1 week ago
IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation
POTOMAC, MARYLAND / ACCESS Newswire / June 30, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders, today unveiled the key achievements and advancements that defined Fiscal Year 2025, ended March 31, 2025. This past year has been nothing short of transformative, marked by significant clinical progress, strategic expansion, and growing recognition for our pioneering approach to Alzheimer's disease.
Neutral
Zacks Investment Research
2 weeks ago
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.04 per share a year ago.
Neutral
Accesswire
2 weeks ago
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025
POTOMAC, MARYLAND / ACCESS Newswire / June 27, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company will host a conference call and webcast on Monday, June 30, 2025, at 11:00 a.m. Eastern Time to review the Company's operational progress for the fiscal year ended March 31, 2025.
Neutral
Accesswire
2 weeks ago
IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon
POTOMAC, MD / ACCESS Newswire / June 23, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the addition of a new clinical trial site at Tekton Research in Yukon, Oklahoma, for its Phase 2 CALMA study evaluating IGC-AD1 for agitation in Alzheimer's dementia. This expansion into the Oklahoma City metropolitan area underscores IGC's commitment to diversifying its trial population and addressing regional healthcare disparities.
Neutral
Accesswire
1 month ago
IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market
POTOMAC, MD / ACCESS Newswire / May 22, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA Phase 2 clinical trial, investigating IGC-AD1 for agitation in Alzheimer's disease. This strategic site directly addresses the significant impact of Alzheimer's in the region.
Neutral
Accesswire
2 months ago
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting
POTOMAC, MD / ACCESS Newswire / May 12, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it presented its latest scientific poster, titled "Genetic Toxicity Evaluation of Melatonin in the Bacterial Reverse Mutation Assay," at the 2025 Genetic Toxicology Association Annual Meeting, showcasing key non-clinical data that support the genetic safety profile of one of the two active pharmaceutical ingredients ("API") in IGC-AD1, the Company's investigational drug for Alzheimer's disease. Part of the FDA's battery of safety requirements is to show that APIs are safe for human consumption, including that they do not alter or mutate genes.
Neutral
Accesswire
2 months ago
IGC Pharma Welcomes Strategic Investment from Advisors
POTOMAC, MARYLAND / ACCESS Newswire / April 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company's recently appointed advisors entered into a Share Purchase Agreement (the "SPA") on April 21, 2025, for the purchase of common shares from the Company. The investment, subject to the terms and conditions set forth in the SPA, is for approximately $475 thousand at the higher of 30 cents or $0.01 over the last closing price.
Neutral
Accesswire
2 months ago
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs
Industry Veterans Bring Deep Strategic Experience to Guide Alzheimer's Clinical Expansion and Commercial Strategy POTOMAC, MARYLAND / ACCESS Newswire / April 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of Frank Zaccanelli, Robert K. Coughlin, and Joseph Mangan to its Board of Advisors.
Neutral
Accesswire
3 months ago
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program
POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial with the addition of Butler Hospital's Memory and Aging Program, a nationally recognized research center affiliated with the Warren Alpert Medical School of Brown University, in Providence, Rhode Island. The site will support enrollment for the CALMA study evaluating IGC-AD1, IGC Pharma's investigational therapy for agitation in Alzheimer's disease, a condition affecting a majority of Alzheimer's patients and significantly impacting caregivers.
Charts implemented using Lightweight Charts™